JPWO2020154696A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020154696A5 JPWO2020154696A5 JP2021542385A JP2021542385A JPWO2020154696A5 JP WO2020154696 A5 JPWO2020154696 A5 JP WO2020154696A5 JP 2021542385 A JP2021542385 A JP 2021542385A JP 2021542385 A JP2021542385 A JP 2021542385A JP WO2020154696 A5 JPWO2020154696 A5 JP WO2020154696A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- anucleated
- cell
- cells
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024208036A JP2025023108A (ja) | 2019-01-25 | 2024-11-29 | 無核細胞由来のワクチン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797185P | 2019-01-25 | 2019-01-25 | |
| US201962797187P | 2019-01-25 | 2019-01-25 | |
| US62/797,187 | 2019-01-25 | ||
| US62/797,185 | 2019-01-25 | ||
| US201962933302P | 2019-11-08 | 2019-11-08 | |
| US201962933301P | 2019-11-08 | 2019-11-08 | |
| US62/933,302 | 2019-11-08 | ||
| US62/933,301 | 2019-11-08 | ||
| PCT/US2020/015098 WO2020154696A1 (en) | 2019-01-25 | 2020-01-24 | Anucleate cell-derived vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024208036A Division JP2025023108A (ja) | 2019-01-25 | 2024-11-29 | 無核細胞由来のワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523027A JP2022523027A (ja) | 2022-04-21 |
| JPWO2020154696A5 true JPWO2020154696A5 (https=) | 2023-02-02 |
| JP2022523027A5 JP2022523027A5 (https=) | 2023-02-02 |
Family
ID=69780287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542385A Pending JP2022523027A (ja) | 2019-01-25 | 2020-01-24 | 無核細胞由来のワクチン |
| JP2024208036A Pending JP2025023108A (ja) | 2019-01-25 | 2024-11-29 | 無核細胞由来のワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024208036A Pending JP2025023108A (ja) | 2019-01-25 | 2024-11-29 | 無核細胞由来のワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220105166A1 (https=) |
| EP (1) | EP3914722A1 (https=) |
| JP (2) | JP2022523027A (https=) |
| KR (1) | KR20210121106A (https=) |
| CN (1) | CN113614237A (https=) |
| AU (1) | AU2020212601A1 (https=) |
| CA (1) | CA3127665A1 (https=) |
| WO (1) | WO2020154696A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7523203B2 (ja) | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| SG10201912910PA (en) | 2015-07-09 | 2020-02-27 | Massachusetts Inst Technology | Delivery of materials to anucleate cells |
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| JP7602702B2 (ja) * | 2016-05-03 | 2024-12-19 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 寛容性を誘導するための生体分子の細胞内送達 |
| US11624061B2 (en) | 2017-04-28 | 2023-04-11 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| AU2018256925B2 (en) | 2017-04-28 | 2024-11-21 | Agrospheres, Inc. | Compositions and methods for the encapsulation and scalable delivery of agrochemicals |
| BR112020005803A2 (pt) | 2017-09-25 | 2020-12-01 | Agrospheres, Inc. | composições e métodos para produção e administração moduláveis de produtos biológicos |
| US12599656B2 (en) | 2018-03-12 | 2026-04-14 | Stemcell Technologies Canada Inc. | Methods for treating HPV-associated diseases |
| CA3131701A1 (en) | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| US11679388B2 (en) | 2019-04-08 | 2023-06-20 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
| WO2020252215A1 (en) | 2019-06-12 | 2020-12-17 | Cellfe, Inc. | Methods and systems for cell labeling and imaging |
| EP4013392B1 (en) * | 2019-09-13 | 2026-04-29 | Exocure Sweden AB | Use of ghost nanovesicles as therapeutics |
| JP7642813B2 (ja) | 2020-11-18 | 2025-03-10 | セルフィー、インク． | 生体細胞へのメカノポレーションベースのペイロード送達のための方法及びシステム |
| US12227729B2 (en) | 2020-12-24 | 2025-02-18 | Cellfe, Inc. | Methods and systems for high-throughput cell processing |
| TW202241466A (zh) | 2020-12-29 | 2022-11-01 | 美商Ｓｑｚ生物科技公司 | 以經修飾ｐｂｍｃ治療癌症之方法 |
| US20220296691A1 (en) * | 2020-12-29 | 2022-09-22 | Sqz Biotechnologies Company | Methods for treating cancer with activating antigen carriers |
| JP2024503279A (ja) | 2020-12-29 | 2024-01-25 | スクイーズ バイオテクノロジーズ カンパニー | Ｐｂｍｃの凍結保存のための製剤 |
| US20220233676A1 (en) | 2020-12-29 | 2022-07-28 | Sqz Biotechnologies Company | Formulations of activating antigen carriers |
| WO2023010090A1 (en) | 2021-07-29 | 2023-02-02 | Sqz Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| WO2023087009A1 (en) | 2021-11-11 | 2023-05-19 | Sqz Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| CA3262748A1 (en) | 2022-07-28 | 2024-02-01 | Stemcell Technologies Canada Inc. | IMPROVED ANTIGEN-PRESENTING CELL FORMULATIONS |
| CA3262756A1 (en) | 2022-07-28 | 2024-02-01 | Stemcell Technologies Canada Inc. | CANCER TREATMENT METHODS WITH ENHANCED ANTIGEN-PRESENTING CELLS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2150617C (en) * | 1995-02-07 | 2001-10-30 | Universite Laval | Nanoerythrosome as bioactive agent carrier |
| WO2005121369A2 (en) * | 2004-06-02 | 2005-12-22 | Sourcepharm, Inc. | Rna-containing microvesicles and methods therefor |
| US8329161B2 (en) * | 2008-05-01 | 2012-12-11 | National Health Research Institutes | Red blood cell-derived vesicles as a nanoparticle drug delivery system |
| CN107058101B (zh) * | 2011-10-17 | 2021-06-01 | 麻省理工学院 | 细胞内传递 |
| EP3033184B1 (en) | 2013-08-16 | 2021-03-31 | Massachusetts Institute of Technology | Selective delivery of material to cells |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| JP7523203B2 (ja) | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| WO2016077761A1 (en) | 2014-11-14 | 2016-05-19 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
| SG10201912910PA (en) * | 2015-07-09 | 2020-02-27 | Massachusetts Inst Technology | Delivery of materials to anucleate cells |
| ES2930017T3 (es) * | 2015-09-04 | 2022-12-05 | Sqz Biotechnologies Co | Suministro intracelular de biomoléculas mediado por una superficie con poros |
| JP7602702B2 (ja) * | 2016-05-03 | 2024-12-19 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 寛容性を誘導するための生体分子の細胞内送達 |
-
2020
- 2020-01-24 WO PCT/US2020/015098 patent/WO2020154696A1/en not_active Ceased
- 2020-01-24 JP JP2021542385A patent/JP2022523027A/ja active Pending
- 2020-01-24 CA CA3127665A patent/CA3127665A1/en active Pending
- 2020-01-24 KR KR1020217026565A patent/KR20210121106A/ko active Pending
- 2020-01-24 CN CN202080023790.9A patent/CN113614237A/zh active Pending
- 2020-01-24 EP EP20710333.4A patent/EP3914722A1/en active Pending
- 2020-01-24 US US17/425,709 patent/US20220105166A1/en active Pending
- 2020-01-24 AU AU2020212601A patent/AU2020212601A1/en active Pending
-
2024
- 2024-11-29 JP JP2024208036A patent/JP2025023108A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020154696A5 (https=) | ||
| Hotaling et al. | Biomaterial strategies for immunomodulation | |
| Veerman et al. | Immune cell-derived extracellular vesicles–functions and therapeutic applications | |
| JP2025023108A (ja) | 無核細胞由来のワクチン | |
| AU2018203586B2 (en) | Tumor lysate loaded particles | |
| Liu et al. | Enhanced antitumor immune responses via a self-assembled carrier-free nanovaccine | |
| JP2007528848A (ja) | ワクチン接種ノードを用いるプログラムされた免疫応答 | |
| AU2023263417A1 (en) | Tolerizing immune modifying nanoparticles for overcoming the immunogenicity of therapeutic vectors and proteins | |
| AU2020203845C1 (en) | Tumor lysate loaded particles | |
| US20260041747A1 (en) | T cell epitopes associated with type 1 diabetes | |
| Srinivasan et al. | Dendritic cells support a proliferative antigen‐specific T‐cell response in the presence of poly (lactic‐co‐glycolic acid) | |
| US20240350540A1 (en) | Tumor lysate loaded particles | |
| CA2883949C (en) | Tumor lysate loaded particles | |
| Garapaty et al. | Biomimetic and synthetic interfaces to tune immune responses | |
| CN104936612A (zh) | 装载了肿瘤裂解物的微粒 | |
| JP2026511042A (ja) | 重症筋無力症の治療のための寛容化免疫修飾ナノ粒子 | |
| WO2024243524A1 (en) | Treatment of type 1 diabetes (t1d) with tolerizing nanoparticles |